Therapeutic Targeting of Neuroendocrine Prostate Cancer

Abstract

Neuronedocrine prostate cancer is an advanced form of this disease with very limited option of effective treatment. It has been shown that BRN2 is highly expressed in NEPC, and preliminary in vitro data show that inhibition of BRN2 decreases tumor cells growth. We will perform preclinical evaluation of efficacy of a novel BRN2 inhibitor alone, in combination with carboplatin (a standard therapy for neuroendocrine prostate cancer) to determine whether this treatment inhibits progression of NEPC and provides survival benefits.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2020
Accession Number
AD1112430

Entities

People

  • Eva Corey

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Body Weight
  • Cancer
  • Castration
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Covid-19
  • Genes
  • Genetics
  • Genomics
  • Molecules
  • Neoplasms
  • Prostate Cancer
  • Proteins
  • Small Molecules
  • Standards
  • Stem Cells
  • Targeting
  • Therapy
  • Transcription Factors

Fields of Study

  • Biology
  • Medicine

Readers

  • Allergy and Immunology.
  • Oncology
  • Oncology (Cancer Research).